Key stats
- 100M commercial devices shipped annually
- 1M ft2 cGMP footprint
- 2,000+ employees
- 10 manufacturing and R&D facilities globally
Who is Kindeva?
We are a finished-dose contract development and manufacturing organization (CDMO) driven by the belief that every patient deserves tomorrow. Leveraging specialist injectable, pulmonary, nasal and dermal expertise, our team harnesses our global manufacturing and R&D facilities to develop innovative solutions that advance your project, your ambitions and the future of drug delivery.
Finished dose CDMO expertise
We invest in state-of-the-art facilities, cutting-edge technologies and advanced analytical capabilities to deliver strategic value that extends beyond manufacturing across:
- Sterile injectables: Seamless integration of device manufacture, sterile fill-finish and final assembly.
- Pulmonary & Nasal: Development and manufacturing of a full range of pulmonary drug delivery products and full-service support for nasal administration, including Green Propellants and pMDIs.
- Dermal: Proven innovation in drug-in-adhesive transdermal patches and next-generation intradermal delivery systems like microneedle array patches.
Exceptional-by-design CDMO solutions
Our comprehensive drug delivery CDMO solutions accelerate your path to market while optimizing your supply chain and minimizing environmental impact. From development to commercial manufacturing and beyond, our CDMO solutions are designed to help your product progress with purpose.
- Development: Expert team and a development-by-design approach.
- Manufacturing: Scalable solutions from clinical trials to commercial production.
- Analytical: Comprehensive testing and characterization services.
- Fill finish: State-of-the-art facilities with high-speed lines and Annex-1 compliance.
- Regulatory: Support for navigating the global regulatory landscape.
At DCAT Week 2025, Kindeva is unveiling a bold new chapter.
Book a meeting with the Kindeva team and let’s make your future.
You dream it, we deliver it.
